Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
about
Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literatureBile acids as metabolic regulatorsFarnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cellsBile acid signaling in metabolic disease and drug therapyCoordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 DiabetesEffect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translationIntestinal transport and metabolism of bile acidsLipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiationBile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery.Specific inhibition of bile acid transport alters plasma lipids and GLP-1Implications of microbiota and bile acid in liver injury and regeneration.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunctionElevated First-Trimester Total Bile Acid is Associated with the Risk of Subsequent Gestational Diabetes.OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.Cholesteryl ester transfer protein protects against insulin resistance in obese female mice.Potential mediators linking gut bacteria to metabolic health: a critical view.GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation.Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways.The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders.Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes.The bile acid TGR5 membrane receptor: from basic research to clinical application.Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract.Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes.Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro.Intestinal bile acid receptors are key regulators of glucose homeostasis.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Roles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling.Bile Acid Uptake Transporters as Targets for Therapy.Bile acids and bariatric surgery.Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.Bile acids in glucose metabolism in health and disease.
P2860
Q27010589-7EB56C25-FCCF-4845-AB15-2B223E902D5EQ27022441-D1A0CDA8-2894-426F-A5FF-ED3C4F703BB3Q27324038-E6DA30DE-46D0-400D-827F-5FFD99860537Q28244875-C1052C71-A9F2-4A21-BD5D-123DE30F3170Q33608251-384629E3-C1B5-417C-97F0-9FA6503538B5Q33818877-1EFFA681-8EBB-429A-A8FE-5D17C9DBEA25Q33890208-66E6396B-846A-4FFF-9C3B-989F801CD414Q34425909-CB24C90C-3933-44DC-8C58-5737CD621E79Q35145474-A365A22E-FED0-4BC0-8DF2-B19A81BB687EQ35247159-EEF1B312-5E83-4080-92A1-D3EA7E9D27A8Q35693608-C74BAB3A-E2E4-451A-8249-B31039AE5809Q35703158-E2BB6A41-EF7C-4C70-8663-2A255B9DF475Q35703890-F42C5F2C-AFEC-4B0F-A9E6-A32A61B5D1C3Q35740865-319E65C5-EA2C-4817-AE4F-91B95B18E2F5Q36237911-F71C6361-A4DE-46C1-840B-74EDBDFD9FC9Q36379436-F80D463A-3D82-4053-A450-39E9736BC73CQ37282320-D0747F3B-F414-41FF-A3DC-93B1F07A3E58Q37325663-92D9C7A4-1EB8-42B2-9DE5-840675CA564AQ37372858-121FA92F-3CEB-46CA-8FCC-9DEC4F6331B7Q37583957-51E1F658-52E0-4179-81A9-D928BD22B4B0Q37635259-0142C4EB-EA33-457F-B31E-1A905B14E940Q37699321-936857AB-430F-48AC-9AF5-5B5C1D8AB029Q38115636-EA723FF0-0B21-4F59-AF8E-7B0F90F1EE31Q38172109-17D5981F-2571-4197-B2AE-5EC429B4EFEBQ38177434-452431AF-8EE9-472F-A6E7-D419290BBBC0Q38194905-E52A6C91-90B3-4A65-8B52-9AA9D389EC08Q38195530-293B9B7E-1757-4167-8586-753AE6BF5251Q38231646-EA24E517-7A0C-4926-A831-ABED7A9D23B3Q38820260-C15D1545-2C2B-4DE2-937F-FB7FF2D67396Q38831400-019C35BE-2409-4641-AF3E-783341B75E42Q39009492-CD22E497-9A14-4D64-A4B9-1A1213852B08Q39044702-1485EACB-D221-4882-BEF6-ACB822123FECQ39156527-275CD13E-CB80-4D1D-AF53-BBB89013F372Q39156569-D4F16E3C-597D-4FC3-9C5A-EEF19B5EB948Q39228891-E5880C55-A192-4AA2-9B19-2798A603542DQ39989391-5120B60E-8CD9-4501-B20A-120BA5BF193FQ42363893-53C65F3D-ECC9-4022-93CF-DA0B5EAD12A0Q42725751-F45516A4-639C-44B6-9A64-C9216594FDA4Q47979742-3E5185A8-40C4-48CF-A4E0-7A0F5DF93685Q48042610-0F6205E1-ED3F-4C69-B489-F73E4D9D7BB3
P2860
Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Colesevelam suppresses hepatic ...... n of GLP-1 action in DIO mice.
@en
type
label
Colesevelam suppresses hepatic ...... n of GLP-1 action in DIO mice.
@en
prefLabel
Colesevelam suppresses hepatic ...... n of GLP-1 action in DIO mice.
@en
P2093
P2860
P356
P1476
Colesevelam suppresses hepatic ...... on of GLP-1 action in DIO mice
@en
P2093
Austin Potts
João A G Duarte
Ronald Taussig
Shawn C Burgess
Steven A Kliewer
Tianteng He
P2860
P304
P356
10.1152/AJPGI.00400.2012
P577
2012-12-20T00:00:00Z